University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen

Hospital


Location: Groningen, Netherlands (NL) NL

ISNI: 0000000095584598

ROR: https://ror.org/03cv38k47

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

DNAm landscape up to 4 months post SARS-CoV-2 infection: insights from four population-based cohorts (2026) Matías-García PR, Lai L, Delerue T, Ohnmacht J, Stark KJ, Warmerdam R, Kolodkin A, et al. Journal article Toward standardized care: International expert survey on pregnancy management in long-chain fatty acid oxidation disorders and unmet needs (2026) Zeyer KA, Derks TG, Langeveld M, Murphy E, Rossi A, Spiekerkoetter U, Wagenmakers M, et al. Journal article Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review (2026) Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, et al. Journal article Translating ctDNA into cutaneous melanoma care: An international expert survey (2026) Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, et al. Journal article Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis (2026) Kugathasan L, Nardone M, Muskiet MH, Diaz Martinez JP, Lovblom LE, Orchanian-Cheff A, Nielsen S, et al. Journal article Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC (2026) Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, et al. Journal article Fumarate hydratase-deficient renal cell carcinoma – results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment (2026) Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, et al. Journal article Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals (2026) Neuen BL, Major RW, Grams ME, Sang Y, Coresh J, Ballew SH, Surapaneni A, et al. Journal article Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling (2026) Suissa D, Fidelle M, Reich E, Pham TN, Thomas S, Björk JR, Liu P, et al. Journal article Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure (2026) Agarwal R, Correa-Rotter R, Navaneethan SD, Heerspink HJ, Weir MR, McGill JB, Mottl AK, et al. Journal article